Minor Bleeds Alert for Subsequent Major Bleeding in Patients Using Vitamin K Antagonists.

Article English OPEN
Veeger , Nic J.G.M.; Piersma-Wichers , Margriet; Meijer , Karina; Hillege , Hans L.;

International audience; Vitamin K antagonists (VKA) have shown to be effective in primary and secondary prevention of thromboembolism, but the associated risk of bleeding is an important limitation. The majority of the bleeds are clinically mild. In this study, we asses... View more
  • References (20)
    20 references, page 1 of 2

    Albers,G.W., Diener,H.C., Frison,L., Grind,M., Nevinson,M., Partridge,S., Halperin,J.L., Horrow,J., Olsson,S.B., Petersen,P., & Vahanian,A. (2005) Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. JAMA, 293, 690- 698.

    Allison,P.D. (1995) Survival Analysis Using the SASĀ® System: A Practical Guide, pp. 1-292. Cary, NC: SAS Institute Inc..

    Ansell,J., Hirsh,J., Hylek,E., Jacobson,A., Crowther,M., & Palareti,G. (2008) Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians EvidenceBased Clinical Practice Guidelines (8th Edition). Chest, 133, 160S-198S.

    Azar,A.J., CannegieterF,S.C., Deckers,J.W., Briet,E., van Bergen,P.F., Jonker,J.J., & Rosendaal,F.R. (1996) Optimal intensity of oral anticoagulant therapy after myocardial infarction. J Am.Coll.Cardiol., 2o7,1349-1355.

    Beyth,R.J., Quinn,L.M., & Landrefeld,C.S. (1998) Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am.J.Med., 105, 91-99. P

    Connolly,S.J., Ezekowitz,M.D., Yusuf,S., Eikelboom,J., Oldgren,J., Parekh,A., Pogue,J., Reilly,P.A., Themeles,E., Varrone,J., Wange,S., Alings,M., Xavier,D., Zhu,J., Diaz,R., Lewis,B.S., Darius,H., Diener,H.C., Joyner,C.D., & Wallentin,L. (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N.Enegl.J.Med., 361, 1139-1151.

    DiMarco,J.P., Flaker,G., Waldo,A.L., Corley,Sr.D., Greene,H.L., Safford,R.E., Rosenfeld,L.E., Mitrani,G., & Nemeth,M. (2005) Factors affecting bleeding risk during anticoagulant therapy in patients with atrial fibrillation: observations Rfrom the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. Am.Heart J., 149, 650-656.

    Fihn,S.D., Gadisseur,A.A., Pasterkamp,E., van der Meeer,F.J., Breukink-Engbers,W.G., GevenBoere,L.M., van Meegen,E., Vries-Goldschmedingv,H., Antheunissen-Anneveld,I., van't Hoff,A.R., Harderman,D., Smink,M., & Rosendaal,F.R. (2003) Comparison of control and stability of oral anticoagulant therapy using acenocoumiarol versus phenprocoumon. Thromb.Haemost., 90, 260-266.

    Gage,B.F. & Lesko,L.J. (2008) Pharmacogenetics of warfarin: reguwlatory, scientific, and clinical issues. J.Thromb.Thrombolysis., 25, 45-51.

    Go,A.S., Hylek,E.M., Chang,Y., Phillips,K.A., Henault,L.E., Capra,A.M., Jensvold,N.G., Selby,J.V., & Singer,D.E. (2003) Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice? JAMA, 290, 2685-2692.

  • Metrics
Share - Bookmark